ADDED
These forward-looking statements address various matters, including the Company s strategy, planned future operations and related expectations with respect to timing and performance, future financial position, future revenues, growth potential and expected growth drivers, the timing, performance and anticipated benefits of collaboration, partnership and licensing activities, projected costs and capital expenditures, prospects and plans, and objectives of management.
INDUSTRY AND MARKET DATA This Annual Report on Form 10-K may include data obtained from third-party research and industry publications, surveys and studies.
The Company believes that these third-party research and industry publications, surveys and studies are reliable, but has not independently verified the accuracy or completeness of such information.
This Annual Report on Form 10-K also may include data based on the Company s own internal estimates and research, which have not been verified by any independent source.
Any such third-party data, as well as the Company s internal estimates and research, are subject to uncertainty and risk due to a variety of factors, including those described in Part I, Item 1A, Risk Factors and elsewhere in this Annual Report on Form 10-K, which could cause the Company s results to differ materially from those expressed in this Annual Report on Form 10-K.
Trademarks The NeoGenomics and Inivata company names and certain logos have been trademarked with the United States Patent and Trademark Office.
We have trademarked or have applications pending for the brand names NEO COMPREHENSIVE, NEO EXPAND, NEOLINK, NEOLAB, NEOACCESS, NEOTYPE, NEOSITE, CHART, COMPASS, eCOMPASS, FLEXREPORT, HEMEFISH, MULTIOMYX, NEOVUE, NEOHELIX, NEONET, NEOLYTX, NEOACCELERATE, NEOENGAGE, NEOPIXEL, NEONUCLEUS, NEOSEEK, NEOEXPLORE, NEOUNIVERSITY, PATHSITE, TAM-SEQ, INVISION, INVISIONSEQ, INVISIONFIRST, INVISIONFIRST-LUNG, PANTRACER, RADAR, NEORADAR, NEOGENOMICS EUROPE, AML EXPRESS, AND PALETRRA.
We also have trademarked for the marketing slogans TAKING CANCER PERSONALLY.
Glossary Throughout this Annual Report on Form 10-K, we may use certain abbreviations, acronyms and terms, including those described below: ACA The Patient Protection and Affordable Care Act ACLA American Clinical Laboratory Association AKS Anti-Kickback Statute CAP College of American Pathologists CGP Comprehensive Genetic Profile CLIA Clinical Laboratory Improvement Amendments of 1988 CMS Centers for Medicare and Medicaid Services CRO Contract research organizations DHS Designated health services FCA The federal False Claims Act FDA U.S.
Our common stock is listed on The Nasdaq Stock Market LLC ( Nasdaq ) under the symbol NEO.
REMOVED
These forward-looking statements address various matters, including the Company s strategy, future operations, future financial position, future revenues, changing reimbursement levels from government payers and private insurers, projected costs, prospects and plans, and objectives of management.
Trademarks The NeoGenomics , Genoptix , Clarient , Inivata , and Trapelo company names and certain logos have been trademarked with the United States Patent and Trademark Office.
We have trademarked or have applications pending for the brand names NEO COMPREHENSIVE, NEO EXPAND, NEOLINK, NEOLAB, NEOACCESS, NEOTYPE, NEOSITE, CHART, COMPASS, eCOMPASS, FLEXREPORT, HEMEFISH, MULTIOMYX, NEOVUE, NEOHELIX, NEONET, NEOLYTX, NEOACCELERATE, NEOENGAGE, NEOPIXEL, NEONUCLEUS, NEOSEEK, NEOEXPLORE, NEOUNIVERSITY, PATHSITE, QUICKPATH, TAM-SEQ, INVISION, INVISIONSEQ, INVISIONFIRST, INVISIONFIRST-LUNG, INVISIONSCAN, PANTRACER, RADAR, and NEORADAR.
We also have trademarked or have pending trademarks for the marketing slogans SERVING PATIENTS, SAVING LIVES , TAKING CANCER PERSONALLY , and UNIVERSAL FUSION EXPRESSION .
Glossary Throughout this 2024 Form 10-K, we may use certain abbreviations, acronyms and terms which are described below: ACA The Patient Protection and Affordable Care Act ACLA American Clinical Laboratory Association AKS Anti-Kickback Statute CAP College of American Pathologists CDx Companion Diagnostic CGP Comprehensive Genetic Profile CLIA Clinical Laboratory Improvement Amendments of 1988 CMS Centers for Medicare and Medicaid Services CRO Contract research organizations DHS Designated health services FCA The federal False Claims Act FDA U.S.
Our common stock is listed on The Nasdaq Stock Market LLC ( Nasdaq ) under the symbol NEO .
As of December 31, 2024, the Company operated College of American Pathologists ( CAP ) accredited and Clinical Laboratory Improvement Amendments of 1988 ( CLIA ) certified laboratories in Fort Myers, Florida; Aliso Viejo and Carlsbad, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom.
Flow cytometry is also used to monitor patients during the course of therapy to identify extremely low levels of residual malignant cells, known as minimal residual disease ( MRD ) monitoring.
Most molecular techniques rely on the analysis of DNA and/or RNA, as well as the structure and function of genes at the molecular level.
Morphologic analysis may be performed on a wide variety of samples, such as peripheral blood, bone marrow, lymph nodes, and other sites such as lung, breast, etc.